Cargando…
A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer
In recent years, three PARP inhibitors and three CDK4/6 inhibitors have been approved by the FDA for the treatment of recurrent ovarian cancer and advanced ER-positive breast cancer, respectively. However, the clinical benefits of the PARPi or CDK4/6i monotherapy are not as satisfied as expected and...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911181/ https://www.ncbi.nlm.nih.gov/pubmed/35270034 http://dx.doi.org/10.3390/ijms23052892 |
_version_ | 1784666723729801216 |
---|---|
author | Tian, Chenchen Wei, Yufan Li, Jianjun Huang, Zhi Wang, Qiong Lin, Yingxue Lv, Xingping Chen, Yanan Fan, Yan Sun, Peiqing Xiang, Rong Chang, Antao Yang, Shuang |
author_facet | Tian, Chenchen Wei, Yufan Li, Jianjun Huang, Zhi Wang, Qiong Lin, Yingxue Lv, Xingping Chen, Yanan Fan, Yan Sun, Peiqing Xiang, Rong Chang, Antao Yang, Shuang |
author_sort | Tian, Chenchen |
collection | PubMed |
description | In recent years, three PARP inhibitors and three CDK4/6 inhibitors have been approved by the FDA for the treatment of recurrent ovarian cancer and advanced ER-positive breast cancer, respectively. However, the clinical benefits of the PARPi or CDK4/6i monotherapy are not as satisfied as expected and benefit only a fraction of patients. Current studies have shown therapeutic synergy for combinations of PARPi and CDK4/6i in breast and ovarian cancers with homologous recombination (HR) proficiency, which represents a new synthetic lethal strategy for treatment of these cancers regardless HR status. Thus, any compounds or strategies that can combine PARP and CDK4/6 inhibition will likely have great potential in improving clinic outcomes and in benefiting more patients. In this study, we developed a novel compound, ZC-22, that effectively inhibited both PARP and CDK4/6. This dual-targeting compound significantly inhibited breast and ovarian cancer cells by inducing cell cycle arrest and severe DNA damage both in vitro and in vivo. Interestingly, the efficacy of ZC-22 is even higher than the combination of PARPi Olaparib and CDK4/6i Abemaciclib in most breast and ovarian cancer cells, suggesting that it may be an effective alternative for the PARPi and CDK4/6i combination therapy. Moreover, ZC-22 sensitized breast and ovarian cancer cells to cisplatin treatment, a widely used chemotherapeutic agent. Altogether, our study has demonstrated the potency of a novel CDK4/6 and PARP dual inhibitor, which can potentially be developed into a monotherapy or combinatorial therapy with cisplatin for breast and ovarian cancer patients with HR proficiency. |
format | Online Article Text |
id | pubmed-8911181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89111812022-03-11 A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer Tian, Chenchen Wei, Yufan Li, Jianjun Huang, Zhi Wang, Qiong Lin, Yingxue Lv, Xingping Chen, Yanan Fan, Yan Sun, Peiqing Xiang, Rong Chang, Antao Yang, Shuang Int J Mol Sci Article In recent years, three PARP inhibitors and three CDK4/6 inhibitors have been approved by the FDA for the treatment of recurrent ovarian cancer and advanced ER-positive breast cancer, respectively. However, the clinical benefits of the PARPi or CDK4/6i monotherapy are not as satisfied as expected and benefit only a fraction of patients. Current studies have shown therapeutic synergy for combinations of PARPi and CDK4/6i in breast and ovarian cancers with homologous recombination (HR) proficiency, which represents a new synthetic lethal strategy for treatment of these cancers regardless HR status. Thus, any compounds or strategies that can combine PARP and CDK4/6 inhibition will likely have great potential in improving clinic outcomes and in benefiting more patients. In this study, we developed a novel compound, ZC-22, that effectively inhibited both PARP and CDK4/6. This dual-targeting compound significantly inhibited breast and ovarian cancer cells by inducing cell cycle arrest and severe DNA damage both in vitro and in vivo. Interestingly, the efficacy of ZC-22 is even higher than the combination of PARPi Olaparib and CDK4/6i Abemaciclib in most breast and ovarian cancer cells, suggesting that it may be an effective alternative for the PARPi and CDK4/6i combination therapy. Moreover, ZC-22 sensitized breast and ovarian cancer cells to cisplatin treatment, a widely used chemotherapeutic agent. Altogether, our study has demonstrated the potency of a novel CDK4/6 and PARP dual inhibitor, which can potentially be developed into a monotherapy or combinatorial therapy with cisplatin for breast and ovarian cancer patients with HR proficiency. MDPI 2022-03-07 /pmc/articles/PMC8911181/ /pubmed/35270034 http://dx.doi.org/10.3390/ijms23052892 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tian, Chenchen Wei, Yufan Li, Jianjun Huang, Zhi Wang, Qiong Lin, Yingxue Lv, Xingping Chen, Yanan Fan, Yan Sun, Peiqing Xiang, Rong Chang, Antao Yang, Shuang A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer |
title | A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer |
title_full | A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer |
title_fullStr | A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer |
title_full_unstemmed | A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer |
title_short | A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer |
title_sort | novel cdk4/6 and parp dual inhibitor zc-22 effectively suppresses tumor growth and improves the response to cisplatin treatment in breast and ovarian cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911181/ https://www.ncbi.nlm.nih.gov/pubmed/35270034 http://dx.doi.org/10.3390/ijms23052892 |
work_keys_str_mv | AT tianchenchen anovelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT weiyufan anovelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT lijianjun anovelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT huangzhi anovelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT wangqiong anovelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT linyingxue anovelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT lvxingping anovelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT chenyanan anovelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT fanyan anovelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT sunpeiqing anovelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT xiangrong anovelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT changantao anovelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT yangshuang anovelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT tianchenchen novelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT weiyufan novelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT lijianjun novelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT huangzhi novelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT wangqiong novelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT linyingxue novelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT lvxingping novelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT chenyanan novelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT fanyan novelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT sunpeiqing novelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT xiangrong novelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT changantao novelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer AT yangshuang novelcdk46andparpdualinhibitorzc22effectivelysuppressestumorgrowthandimprovestheresponsetocisplatintreatmentinbreastandovariancancer |